GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyeGene Inc (XKRX:185490) » Definitions » Total Equity

EyeGene (XKRX:185490) Total Equity : ₩53,401 Mil (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is EyeGene Total Equity?

EyeGene's total equity for the quarter that ended in Sep. 2024 was ₩53,401 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


EyeGene Total Equity Historical Data

The historical data trend for EyeGene's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyeGene Total Equity Chart

EyeGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19,029.94 12,899.29 88,969.18 68,955.72 64,334.05

EyeGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54,661.38 64,334.05 59,322.94 56,492.82 53,401.02

EyeGene Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

EyeGene's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=78102.743-13768.697
=64,334

EyeGene's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=67776.474-14375.455
=53,401

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EyeGene Total Equity Related Terms

Thank you for viewing the detailed overview of EyeGene's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


EyeGene Business Description

Traded in Other Exchanges
N/A
Address
Gangseo-gu, Seoul 401, B-dong 910 Gayang-dong, Seoul, KOR, 07528
EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.

EyeGene Headlines

No Headlines